Stay updated on Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.

Latest updates to the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page
- Check3 days agoNo Change Detected
- Check11 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe page shows a new status: Active, not recruiting, and the revision version was updated to v3.4.2. Additionally, a contact phone number and the Recruiting label were removed.SummaryDifference0.3%

- Check40 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1, indicating a minor maintenance update rather than content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check47 days agoChange DetectedNo significant changes detected between the two screenshots; the page content and layout appear unchanged.SummaryDifference0.0%

- Check54 days agoChange DetectedThe Study Record Dates section now shows 'Last Update Posted' instead of 'Last Update Posted (Estimated)'.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision metadata updated from v3.3.3 to v3.3.4; no substantive study content (eligibility criteria, endpoints, locations, or results) appears to be affected. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in ES-SCLC 2nd-line Therapy Clinical Trial page.